Cover Image

The investigation of complex endometrial hyperplasia prevalence by diagnostic curettage and some of riskfactors affiliated to it in ahvaz-razi hospital

Ali Ghomeishi, Mahin Najafian*


The endometrial hyperplasia indicates the wide spectrum of limit variation of endometrial hyperplasia which has changed from intensification of physiological status to carcinoma. The endometrial hyperplasia is the introduction of the endometrial cancer, which is the most common female genital tract malignancy. Studies suggest that abnormal uterine bleeding is the most common indication of the endometrial hyperplasia that is performed for diagnosis of diagnostic curettage. With regard to the mentioned issue of this study, in order to identify factors associated with endometrial hyperplasia have been performed. This cross-sectional study has been performed on one thousand diagnostic curettage specimen’s from 1390 to 1393 (During the last three years) in RaziAhvaz hospital. The specimens based on the presence or absence of endometrial hyperplasia were divided into two groups. Then factors such as age, menstrual pattern, diabetes, hypertension, history of infertility, age over 45years, obesity, use of oral contraceptives were studied and compared. In this study of a thousand cases of diagnostic curettage, because of abnormal uterine bleeding in 160 patients(16%) complex hyperplasia, with factors such as oligomenorrhea38% vs.8/5 % (P<0/0001) and diabetes (28%) versus (P<0/001), hypertension 32% versus 12% (P<0/001), history of infertility, 19% vs. 5/5% (P<0/001), age over 45years, 32% versus 19% (P<0/001), obesity BMI> 30 46% versus 18% (P<0/001), nulliparity 9% versus 1% (P<0/001) had significant relationship with endometrial hyperplasia. But there was no significant relationship with use of oral contraceptive. According to this study, women who were obese and have history of hypertension, diabetes, infertility, menstrual disorders as oligomenorrhea are at high risk for developing endometrial hyperplasia which at last leads to endometrial cancer.


Endometrial Hyperplasia; Risk Factors; abnormal uterine bleeding; Diagnostic Curettage

Full Text:



Haines & Taylor. Obstetrical & Gynaecological Pathology; 5th ed. 2003.

Cullen T. Cancer of the Uterus, Its Pathology, Symptomatology, Diagnosis & Treatment; 1900; A&L; NY.

Fox H. Book review: The Endometrium. Histopathology 1982; 6: 711.

Stephen S. Sternberg. Diaghostic Surgical Pathology; 3rd ed. 1999.

Siegel R, Ward E, Brawleg O. Cancer statistics. Goll, CA cancer J clin zoll; 61:212-36.

Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A Long Term Study of Untreated Hyperplasia, 1985.

Bokhman JV. Two pathologic type of endometrial carcinoma. Gynecol oncol, 1993, 15: 10-A.

Bevek JS, Novak S. Gynecology oncology. 14 th ed philadel phia, Wolters Kluwer 2007:1143-8.

Tinell A, Vergara D, Martignago R, leo G, malvasi A, tinelli K. Hormonal carcinogenesis and sociobiological Factor In endometrial cancer Acta obstet Gynecol scand, 2008; 87 (11): 1101 -13.

Miller G, Bidas MA, pulcini JP, maxwell GL, cosin GA, Rose GS. The ability of endometrial biopsies with atypical hyperplasia to guide surgical management. Am J obstet Gynecol, 2008, 199 (1): 1-4.

Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997; 79: 320-7.

Fechner RE, Kaufman RH. Endometrial adenocarcinoma in Stein-Leventhal syndrome. Cancer, 1974; 34: 444-52.

Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, et al., Cancer risk in families with hereditary non polyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 1020-7.

Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al., Cancer risk in mutation carriers of DNA mismatch repair genes. Int J Cancer 1999; 81: 214-8.

Thornton JG, Brown LA, Wells M, Scott JS. Primary treatment of endometrial cancer with progesterone alone. Lancet 1985; 2: 207-8.

Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol Oncol 1985; 20: 139-55.

Niwa K, Morishita S, Hashimoto M, Yokovama Y, Tamaya T, Conservative therapy for endometrial carcinoma in young women treated with curettage and progestron. Int J Clin Oncol 1997: 2: 165-9.

Kurman RJ, Kaminski PF, Novis HJ. The behavior of endometrial hyper plasia. Along term study of untreated hyperplasia in 170 patients cancer 1985; 56: 403-HR.

Trimble C, Kanderer J, Siluerberg S, Kimura M Otat. Concurrent endometrial carcinoma In women with biopsy diagnosis of atypical endometrial hyper plusia: a cynecology oncology Group study, Lyncool oncol 2004:92:393-6.

Tavassoli F, Kraus FT. Endometrial lesians In Uteri resected for atypical Endimetrial hyper plasia. Am J clin pathol 1978; 70: 770-779.

Hunter JE, Tritz DE, Howell MG, Jordan VC, Juny SM. The prognostic and theraputic Implications of Genicologic atypia In patient with endometrial hyperplasia. Gynecol oncol 1994; 55:66-71.

Hoskins WJ, Perez CA, Young RC. Principals and Practice of Gynaecologic Oncology. 3th ed. Philadelphia, PA: Lippincot Williams and wilkins: 2000; p. 981.

Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984; 64: 417-20.

Weber Am, Belin son JL, piedmonte MR. Risk factor for endometrial hyperplasia and cancer among women with abdomen bleeds. Obstet Gyncol, 1999; 93 (4): 594-98.

Gauceria DA, Bahamondes L, Aldrighi JM, tamanaha S, Ribeir AL, Aoki T. Prevalence of endometrial Ingrain In asymptomatic obese women. Rev Assoc Med Bras 2007; 53 (4):344-8.

Farqahar CM, Lethahy A, Sowter M, Verryt J, Baranyai J. An evaluation of risk factors for endometrial hyperplasia in women with abdomen menstrual bleeding. Am J obstet cynccol 1999; 181 (13):525-9.

Wasson JH, sox HC, Neff RK, Goldman L. Clinical prediction rules: application and method (13): 793-9.

Anastasiadis Pg, S kaphida PG, kout laki NG, Galazios GG, Tsikouras PN, liberis VA. Descriptive epidemiology of endometrial hyperplasia in patient with AUB. Eur J Gyecol 2002; 21 (2): 131-4.

FaraJi R, Esmailpoor N, Behfar B. Assocition of Endometrial hyperplasia with some Risk factors. (JBUMS) Journal of Babl university of medical sciences 2009; vol (11): 22-6.

Ivanov S. Early Finding of Endometrial pre cancer and cancer In women with combined risk factors. Akush Giekol (Sofia) 2006; 45 (6): 45.

Hardiman P, pillay ac, Atima W. Poly cystic ovary syndrome and endometrial carcinima. lancet 2003; 361 (9371): 1810-2.

Balen A. Poly cystic ovary syndrome and cancer. Hum Reprod update 2001; 7 (6): 522-5.

Cheung AP. Ultrasound and menstrual history In predicting endometrial hyperplasia In poly cystic ovary syndrome. obstet Gynecol 2001; 98 (2) : 325-31.

Villavicencio A, Bacallao K, Avellaria C, Gabler F, Fuentes A, Vega M. Androgen and estrogen receptors and regulators level In endometrial from patients with poly cystic ovarian syndrome with and without endometrial hyperplasia. Gynecol oncol 2006; 103 (1): 307-14.

Linkow F, Edwards R, Balk J, newton KM, Holt vl. Endometrial hyperplasia, endometrial cancer and prevention: gaps in existing research of modifiable risk factors. Eur J cancer 2008; 44 (120) 1632-44.



  • There are currently no refbacks.

Copyright (c) 2015 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.